Breaking Free from Corticosteroids in Crohn’s Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf274 ↗Kurz gefasst
Editorial in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Raquel Oliveira und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Unidade Local De Saúde Do Algarve, Portimão, Portugal. Hauptthemen laut MEDLINE: Crohn Disease, Adrenal Cortex Hormones. Die Arbeit nennt 10 Literaturangaben. Gefördert von: AbbVie.
Abstract (Originalsprache)
Lay Summary This editorial discusses the post-hoc analysis by Dubinsky et al. evaluating upadacitinib’s efficacy and safety by baseline corticosteroid use in Crohn’s disease, highlighting its corticosteroid-sparing potential, the need for standardized tapering in trials, and the implications for achieving durable corticosteroid-free remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gastroenterology Department, Unidade Local De Saúde Do Algarve, Portimão, Portugal.
- Algarve Biomedical Centre (ABC), Faro, Portugal.
ORCID-Profile: Raquel Oliveira, Joana Roseira
Förderung
- AbbVie
Zitieren
APA
Oliveira, R., & Roseira, J. (2025). Breaking Free from Corticosteroids in Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf274
Vancouver
Oliveira R, Roseira J. Breaking Free from Corticosteroids in Crohn’s Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf274
BibTeX
@article{Oliveira2025,
author = {Oliveira, Raquel and Roseira, Joana},
title = {Breaking Free from Corticosteroids in Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf274}
}
EUVIMED